EcoDrugPlus

Purinergic Receptor P2x 7

Ensembl ID : ENSSFOG00015007231
Gene Symbol: P2RX7
3 Cross references
191 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3a

Ensembl ID : ENSSFOG00015000840
Gene Symbol: P2RX3A
1 Cross references
192 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3b

Ensembl ID : ENSSFOG00015007047
Gene Symbol: P2RX3B
1 Cross references
198 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSSFOG00015019475
Gene Symbol: P2RY1
3 Cross references
190 Possible Orthologues:

Putative Cyclin-Dependent Serine/threonine-Protein Kinase Ddb_g0272797/ddb_g0274007

Ensembl ID : ENSSFOG00015032503
Gene Symbol: LOC108930668
2 Cross references
191 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSSFOG00015004543
Gene Symbol: P2RY4
3 Cross references
165 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSSFOG00015002205
Gene Symbol: P2RY6
1 Cross references
181 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSSFOG00015033260
Gene Symbol: P2RY6
1 Cross references
181 Possible Orthologues:

Receptor Activity-Modifying Protein 1

Ensembl ID : ENSSFOG00015018531
Gene Symbol: LOC108929013
3 Cross references
252 Possible Orthologues:

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSSFOG00015013668
Gene Symbol: RIPK1
3 Cross references
195 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-2-Like

Ensembl ID : ENSSFOG00015007106
Gene Symbol: LOC108922533
3 Cross references
198 Possible Orthologues:

Receptor-Interacting Serine/threonine-Protein Kinase 1-Like

Ensembl ID : ENSSFOG00015008445
Gene Symbol: LOC108937518
3 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).